Dragonfly In The News
AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player Dragonfly
Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly Therapeutics with AbbVie on cancer drugs as well as autoimmune diseases — a new field for the upstart developer.
Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology
Dragonfly will use its TriNKET(TM) platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology. AbbVie receives exclusive options to license a number of Dragonfly's natural killer (NK) cell engager immunotherapies.
Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home at Bristol-Myers
Today they’re making their first foray into human studies, with the launch of a Phase I study for their lead drug DF1001 in HER2 expressing solid tumors. This is the first of their TriNKET platform drugs to go into humans
Dragonfly Therapeutics Announces Celgene Opt-In of Third TriNKET™ Immunotherapy Drug Candidate
Dragonfly to receive a $12M in-licensing payment and is eligible to receive potential future milestones and royalties on net sales.
Dragonfly Therapeutics Initiates Phase 1/2 Study of DF1001 in Patients with Advanced Solid Tumors
Dragonfly Therapeutics today announced that the first patient was dosed in a Phase 1/2 study of DF1001 at The University of Texas MD Anderson Cancer Center in Houston. Dragonfly's DF 1001 clinical trial is currently recruiting patients with various types of advanced solid tumors that express human epidermal growth factor receptor 2 (HER2).
The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds
Over the last 15 years I’ve had the chance to help select about 200 private biotechs for up-and-coming awards like this. Looking over the rank and file of this disruptive crowd, I had my standouts, my OK borderline selections, and some truly dreadful, cringe-worthy choices.
Dragonfly Founders to Lead Disruptors Conversation at Boston Biotech
Every life sciences startup aims to shake up and challenge the status quo. But which Boston companies are taking the most radical approaches and seem poised to become the biggest disruptors? What are their goals, what is their approach to building a great biotech company, and how are the founders working with investors to pursue their disruptive vision? And most importantly, how will their work impact the lives and health of patients?
Dragonfly, Tyler Jacks’s Disney-Backed Startup, Gets $33M in Celgene Deal
Dragonfly Therapeutics, a stealthy startup formed by well-known cancer researchers on both coasts and backed by a high-powered group of family offices, has inked its first partnership. Celgene, of Summit, NJ, is paying Dragonfly $33 million up front for the chance to co-develop up to four blood cancer drugs.
Celgene bags option on NK cell-based blood cancer assets
Celgene has landed an option on four natural killer (NK) cell-based blood cancer therapeutics in a deal with Dragonfly Therapeutics. The agreement sees Celgene hand over $33 million and commit to more in milestones to access next-generation immuno-oncology candidates aimed at some of its core therapeutic areas.
Dragonfly Therapeutics Strikes Immuno-Oncology Deal With Celgene
Dragonfly Therapeutics Inc. has secured $33 million through a collaboration with Celgene Corp. to develop immuno-oncology treatments for various blood cancers.